Abstract

Objective: To determine the real-world effectiveness of the ChAdOx1 nCoV-19 coronavirus vaccine in preventing severe disease and mortality due to COVID-19. Methods: A case-case design was used to estimate the effect of the ChAdOx1 nCoV-19 coronavirus vaccine on severe SARS-CoV-2 outcomes in individuals aged 40 years and above. Cases (n=200) were COVID-19 patients admitted to intensive care unit (ICU) or who died. Controls (n=223) were those with mild COVID-19, fit for home isolation. The logistic regression model was used to estimate adjusted vaccine effectiveness for full vaccination (two doses ≥14 d) and partial vaccination status (one dose ≥14 d or two doses <14 d). Results: The proportion of fully vaccinated individuals was significantly lower among cases (12, 6.0%) compared to controls (30, 13.5%). The adjusted effectiveness of a full dose of ChAdOx1 nCoV-19 coronavirus vaccine in preventing ICU admission or death was 81.9% (95% CI: 61.3%-91.6%, P=0.001). Subgroup analysis restricted to age group, sex, and comorbidities found that ChAdOx1 nCoV-19 coronavirus vaccine had a significant positive effect in all subgroups and categories. Conclusion: COVID-19 vaccination reduces ICU admissions or death. Therefore, increased vaccine uptake may reduce the severity of the pandemic, more so in the elderly and those with comorbidities.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.